Emergence of succinate dehydrogenase inhibitor resistance of Pyrenophora teres in Europe A Rehfus, S Miessner, J Achenbach, D Strobel, R Bryson, G Stammler Pest Management Science 72 (10), 1977-1988, 2016 | 108 | 2016 |
Computational tools for polypharmacology and repurposing J Achenbach, P Tiikkainen, L Franke, E Proschak Future medicinal chemistry 3 (8), 961-968, 2011 | 89 | 2011 |
VAMMPIRE: a matched molecular pairs database for structure-based drug design and optimization J Weber, J Achenbach, D Moser, E Proschak Journal of medicinal chemistry 56 (12), 5203-5207, 2013 | 52 | 2013 |
Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering D Moser, JM Wisniewska, S Hahn, J Achenbach, E Buscató, FM Klingler, ... ACS Medicinal Chemistry Letters 3 (2), 155-158, 2012 | 50 | 2012 |
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators P Heitel, J Achenbach, D Moser, E Proschak, D Merk Bioorganic & Medicinal Chemistry Letters 27 (5), 1193-1198, 2017 | 43 | 2017 |
Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity R Steri, J Achenbach, D Steinhilber, M Schubert-Zsilavecz, E Proschak Biochemical Pharmacology 83 (12), 1674-1681, 2012 | 42 | 2012 |
Exploring the chemical space of multitarget ligands using aligned self-organizing maps J Achenbach, FM Klingler, R Blöcher, D Moser, AK Häfner, CB Rödl, ... ACS Medicinal Chemistry Letters 4 (12), 1169-1172, 2013 | 37 | 2013 |
Argyreia nervosa (Burm. f.): receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches A Paulke, C Kremer, C Wunder, J Achenbach, B Djahanschiri, A Elias, ... Journal of ethnopharmacology 148 (2), 492-497, 2013 | 36 | 2013 |
Multi-dimensional target profiling of N, 4-diaryl-1, 3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism CB Rödl, D Vogt, SBM Kretschmer, K Ihlefeld, S Barzen, A Brüggerhoff, ... European Journal of Medicinal Chemistry 84, 302-311, 2014 | 33 | 2014 |
Molecular characterization of EP6—A novel imidazo [1, 2-a] pyridine based direct 5-lipoxygenase inhibitor JM Wisniewska, CB Rödl, AS Kahnt, E la Buscató, S Ulrich, Y Tanrikulu, ... Biochemical pharmacology 83 (2), 228-240, 2012 | 30 | 2012 |
In silico models to predict the perturbation of molecular initiating events related to thyroid hormone homeostasis M Garcia de Lomana, AG Weber, B Birk, R Landsiedel, J Achenbach, ... Chemical research in toxicology 34 (2), 396-411, 2020 | 24 | 2020 |
Evaluation of structure-derived pharmacophore of soluble epoxide hydrolase inhibitors by virtual screening D Moser, J Achenbach, FM Klingler, S Hahn, E Proschak Bioorganic & medicinal chemistry letters 22 (21), 6762-6765, 2012 | 24 | 2012 |
KnowTox: pipeline and case study for confident prediction of potential toxic effects of compounds in early phases of development A Morger, M Mathea, JH Achenbach, A Wolf, R Buesen, KJ Schleifer, ... Journal of Cheminformatics 12 (1), 24, 2020 | 20 | 2020 |
Synthetic cannabinoids: In silico prediction of the cannabinoid receptor 1 affinity by a quantitative structure-activity relationship model A Paulke, E Proschak, K Sommer, J Achenbach, C Wunder, SW Toennes Toxicology letters 245, 1-6, 2016 | 20 | 2016 |
Complementary screening techniques yielded fragments that inhibit the phosphatase activity of soluble epoxide hydrolase S Hahn, J Achenbach, E Buscató, FM Klingler, M Schroeder, K Meirer, ... ChemMedChem 6 (12), 2146-2149, 2011 | 19 | 2011 |
PENG: a neural gas-based approach for pharmacophore elucidation. Method design, validation, and virtual screening for novel ligands of LTA4H D Moser, SK Wittmann, J Kramer, R Blöcher, J Achenbach, ... Journal of Chemical Information and Modeling 55 (2), 284-293, 2015 | 16 | 2015 |
VAMMPIRE-LORD: a web server for straightforward lead optimization using matched molecular pairs J Weber, J Achenbach, D Moser, E Proschak Journal of chemical information and modeling 55 (2), 207-213, 2015 | 15 | 2015 |
Identification of novel farnesoid X receptor modulators using a combined ligand-and structure-based virtual screening J Achenbach, M Gabler, R Steri, M Schubert-Zsilavecz, E Proschak MedChemComm 4 (6), 920-924, 2013 | 12 | 2013 |
Pyrazolo [1, 5a] pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors S Hauck, K Hiesinger, SK Hosseini, J Achenbach, RM Biondi, E Proschak, ... Bioorganic & Medicinal Chemistry 24 (22), 5717-5729, 2016 | 11 | 2016 |
Computer-aided selective optimization of side activities of talinolol K Hiesinger, JS Kramer, J Achenbach, D Moser, J Weber, SK Wittmann, ... ACS Medicinal Chemistry Letters 10 (6), 899-903, 2019 | 8 | 2019 |